Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...